Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
Phase of Trial: Phase I/II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Huperzine A (Primary)
- Indications Seizures
- Focus Proof of concept; Therapeutic Use
- Acronyms FIAS
- Sponsors Biscayne Neurotherapeutics
- 28 Mar 2018 According to Biscayne Neurotherapeutics media release, results are expected later in 2018.
- 21 Mar 2018 Status changed from planning to recruiting.
- 19 Oct 2017 According to a Biscayne Neurotherapeutics media release, this trial is expected to begin in early 2018.